SABCS 2025

Questions discussed in this category

In what clinical scenarios, if any, would you consider using sacituzumab govitecan prior to trastuzumab deruxtecan for HR+/HER2- metastatic breast cancer treatment?

ASCENT-07 data recently did not meet the endpoint for progression-free survival for sacituzumab govitecan as a first-line treatment post-endocrine the...

1 Answer available

How will the LORETTA and COMET trials influence your treatment of low-risk DCIS?

6 Answers available

How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?

1 Answer available

What are your top takeaways in Radiation Oncology from SABCS 2025?

1 Answer available

What are your top takeaways in Medical Oncology from SABCS 2025?

3 Answers available

In patients with newly diagnosed HER2+ early breast cancer, what do you anticipate will become the standard sequencing for T-DXd, neoadjuvant (DB11) or adjuvant (DB05) treatment?

Or would you wait for other information/data before incorporating T-DXd in perioperative treatments? Harbeck et al., PMID 41130363

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2025 Dec 10

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

BMJ open, 2025 Aug 27

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

JAMA, 2025 Dec 12

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

Cancer, 2009-04-15

Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation.

Lancet, 2022 Aug 06

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.

JAMA oncology, 2023 Sep 21

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.

The New England journal of medicine, 2024 Dec 12

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014 Nov 04

Evaluation of axillary dose coverage following whole breast radiotherapy: variation with the breast volume and shape.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018 Oct 07

Mapping of the functional anatomy of lymphatic drainage to the axilla in early breast cancer: A cohort study of 933 cases.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017 Jan 04

Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy.

JAMA, 2025 Mar 18

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.

JAMA, 2025 Mar 18

Is It Time to Abandon Surgery for Low-Risk DCIS?

SABCS 2025

Questions discussed in this category

Papers discussed in this category

Related Topics